Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Submitted by shcAdmin on Wed, 12/19/2018 - 15:47
Study ID
DFCI 16-716
Status
Study Information

This study is being conducted by the Alliance for Clinical Trials in Oncology. The Alliance is part of a national research network funded by the National Cancer Institute (NCI). The study will enroll more than 3,000 patients with breast cancer in the United States and Canada. Participants will be randomly assigned (like the flip of a coin) to one of two groups: Weight Loss Intervention Group- Takes part in a telephone-based weight loss program OR Health Education Group- Receives mail or online information about breast cancer topics

Physician
Contact Information

Wendy Loeser RN OCN Clinical Research Dana-Farber Cancer Institute at St. Elizabeth's Medical Center 736 Cambridge St Boston, MA 02135 617-789-3385 Wendy_loeser@DFCI.harvard.edu

Clinical Trial Department
Purpose of Trial
Are you a patient with breast cancer interested in a weight loss program?

If you are, you may be able to help researchers answer an important question: Does losing weight by eating less and exercising lower the risk of cancer recurrence among women who have been diagnosed with early breast cancer? The BWEL Breast Cancer Weight Loss Study aims to answer this question.
Phase
3
Eligibility

You may be eligible to participate if:  You have been diagnosed with stage II-III breast cancer within the last 12 months  You have completed surgery and chemotherapy (if applicable)  You are interested in losing weight and have a body mass index (or BMI) greater than 27 kg/m2  You would like to receive information about health topics  You are willing to be randomly assigned (like a flip of a coin) to one of two groups

Trial conditions